AZD5069

DRUG11 trials

Sponsors

AstraZeneca, Institute of Cancer Research, United Kingdom

Conditions

AUC,Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and NeckAsthmaAsthma,BronchiectasisChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD).Cmax,

Phase 1

Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects

CompletedNCT00953888

AstraZenecaHealthy

Start: 2009-07-31End: 2009-12-31Updated: 2015-06-25

A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Ascending Doses of AZD5069 in Healthy Volunteers

CompletedNCT01051505

AstraZenecaHealthy

Start: 2010-01-31End: 2010-04-30Updated: 2015-06-25

This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose

CompletedNCT01083238

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2010-02-28End: 2010-07-31Target: 24Updated: 2015-06-25

Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069

CompletedNCT01100047

AstraZenecaHealthy

Start: 2010-05-31End: 2011-02-28Updated: 2015-06-25

Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.

CompletedNCT01735240

AstraZenecaAsthma,, AUC,, Cmax, +5

Start: 2012-12-31End: 2013-02-28Updated: 2015-06-25

Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069

CompletedNCT01890148

AstraZenecaAsthma

Start: 2014-03-31End: 2014-08-31Updated: 2016-02-25

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

CompletedNCT01962935

AstraZenecaChronic Obstructive Pulmonary Disease (COPD).

Start: 2013-11-30End: 2014-06-30Updated: 2015-06-25

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

CompletedNCT02499328

AstraZenecaAdvanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Start: 2015-08-06End: 2025-10-08Updated: 2026-02-11

Combination Study of AZD5069 and Enzalutamide.

TerminatedNCT03177187

Institute of Cancer Research, United KingdomMetastatic Castration Resistant Prostate Cancer

Start: 2017-11-13End: 2022-11-16Updated: 2024-09-26

Phase 2

Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis

CompletedNCT01255592

AstraZenecaBronchiectasis, Lung Disease, Respiratory Diseases

Start: 2011-02-28End: 2012-02-29Updated: 2015-10-08

A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.

CompletedNCT01704495

AstraZenecaAsthma

Start: 2012-11-30End: 2014-08-31Updated: 2016-03-01

Related Papers

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

2024-02-0738 citations

Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study

BMJ Open2022-10-0131 citations

Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)

BMJ Open2021-09-013 citations

Abstract 390: Identification of a novel immunosuppressive myeloid gene expression signature for clinical biomarker development

Cancer Research2021-07-01

A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

Annals of Oncology2018-10-0145 citations

Abstract CT103: Rationale for flat dosing of AZD9150 by population pharmacokinetic analysis

Cancer Research2018-07-01

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.

2018-06-0123 citations

Neutrophils in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist AZD5069 - An explorative study in neutrophilic asthma

2016-09-01

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.

2016-08-27210 citations